食道疾病治療藥物市場：按類型、藥物類別、用途- 全球預測 2023-2030

預計2023年全球食道症治療藥物市場將達58,541.9億美元，年複合成長率為4.99%，大幅成長，2030年將達82.436億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球食道藥物市場至關重要。透過檢驗業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球食道症治療藥物市場規模及預測如何？

2.在預測期內，COVID-19對全球食道疾病治療藥物市場的阻礙因素與影響有哪些？

3.預測期內全球食道症治療藥物市場需要投資哪些產品/細分市場/應用/領域？

4.貴公司在全球食道症治療藥物市場的競爭策略為何？

5.全球食道症藥物市場的技術趨勢與法律規範如何？

6.全球食道症治療藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入全球食道藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 食道患者病率上升
    • 採取不健康的生活方式和飲食習慣
    • 質子幫浦抑制劑的使用增加
  • 抑制因素
    • 與食道藥物相關的副作用
  • 機會
    • 藥廠加大研發投入
    • 食道症裝置作為微創手術備受關注
  • 任務
    • 自然療法的替代品
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 食道治療藥物市場：依類型

• 品牌
• 通用的

第7章 食道治療藥物市場

• 氨基水楊酸鹽
• 止瀉藥
• 止吐藥
• 生物製劑/生物相似藥
• 消化酵素
• H2拮抗劑
• 瀉藥
• 質子幫浦抑制劑

第8章 食道治療藥物市場：用途

• 克隆氏症
• 逆流性食道
• 潰瘍性大腸炎

第9章 美洲食道症治療市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太食道症治療市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東和非洲食道症治療市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Gastroesophageal Reflux Disease Therapeutics Market is forecasted to grow significantly, with a projected USD 5,854.19 million in 2023 at a CAGR of 4.99% and expected to reach a staggering USD 8,243.60 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Gastroesophageal Reflux Disease Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Gastroesophageal Reflux Disease Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Branded and Generics. The Generics is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Aminosalicylates, Anti-Diarrheal, Anti-Emetics, Biologics/Biosimilar, Digestive enzymes, H2 Antagonists, Laxatives, and Proton Pump Inhibitors. The Anti-Diarrheal is projected to witness significant market share during forecast period.

Based on Application, market is studied across Crohn's Disease, GERD, and Ulcerative Colitis. The Ulcerative Colitis is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Gastroesophageal Reflux Disease Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Gastroesophageal Reflux Disease Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Gastroesophageal Reflux Disease Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Gastroesophageal Reflux Disease Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Gastroesophageal Reflux Disease Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Gastroesophageal Reflux Disease Therapeutics Market?

6. What is the market share of the leading vendors in the Global Gastroesophageal Reflux Disease Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Gastroesophageal Reflux Disease Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Gastroesophageal Reflux Disease Therapeutics Market, by Type, 2022 vs 2030
• 4.3. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Class, 2022 vs 2030
• 4.4. Gastroesophageal Reflux Disease Therapeutics Market, by Application, 2022 vs 2030
• 4.5. Gastroesophageal Reflux Disease Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of gastroesophageal reflux diseases
    • 5.1.1.2. Adoption of unhealthy lifestyle and eating habits
    • 5.1.1.3. Increasing use of proton pump inhibitors
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects related to the drugs of GERD
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investment by pharma companies in R&D
    • 5.1.3.2. GERD devices gaining traction for minimally invasive procedures
  • 5.1.4. Challenges
    • 5.1.4.1. Alternatives of natural remedies
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Gastroesophageal Reflux Disease Therapeutics Market, by Type

• 6.1. Introduction
• 6.2. Branded
• 6.3. Generics

7. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Aminosalicylates
• 7.3. Anti-Diarrheal
• 7.4. Anti-Emetics
• 7.5. Biologics/Biosimilar
• 7.6. Digestive enzymes
• 7.7. H2 Antagonists
• 7.8. Laxatives
• 7.9. Proton Pump Inhibitors

8. Gastroesophageal Reflux Disease Therapeutics Market, by Application

• 8.1. Introduction
• 8.2. Crohn's Disease
• 8.3. GERD
• 8.4. Ulcerative Colitis

9. Americas Gastroesophageal Reflux Disease Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 5. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 7. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET DYNAMICS
• FIGURE 9. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 5. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-DIARRHEAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS/BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DIGESTIVE ENZYMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GERD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. CHINA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 52. INDIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 104. ITALY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. POLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. QATAR GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 148. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 149. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET LICENSE & PRICING